Brazil's Bold Step Forward in Clinical Research

Brazil is taking significant strides to enhance its clinical research capabilities through a newly launched national initiative. This program aims to streamline processes, increase funding, and integrate research more deeply into the public health system, ultimately benefiting patients and positioning the country as a stronger player in global innovation.

Background and Regulatory Foundations

The foundation for this advancement lies in Law No. 14,874/2024, sanctioned in May 2024 after nearly a decade of deliberation. This legislation modernizes rules for research involving human subjects, providing legal certainty and reducing bureaucratic hurdles that previously deterred investments. The law was regulated in October 2025 through Decree #12,651/2025, which established the National System of Ethics in Research Involving Human Subjects (SINEP) and the National Instance of Ethics in Research (INAEP).

These measures address longstanding challenges such as unpredictable regulatory timelines, import taxation on research supplies, and underutilization of the Unified Health System (SUS). By setting clear 90-business-day response windows for trial applications and emphasizing ethical protections alongside efficiency, Brazil is creating a more attractive environment for both domestic and international collaborators.

Photo by Luan de Oliveira Silva on Unsplash

Launch of the National Clinical Research Program

In April 2026, Health Minister Alexandre Padilha officially launched the National Clinical Research Program (PPClin) during the SUS Inova Brasil Fair in Rio de Janeiro. The initiative, developed in partnership with the Ministry of Science, Technology, and Innovation (MCTI), includes an initial investment of R$120 million to expand clinical research capacity within the public health system.

The program focuses on capacity building, infrastructure modernization, and fostering collaborations between public institutions, private sector partners, and academia. It seeks to address regional inequities and build a more robust, patient-centered research ecosystem.

Key Objectives and Expected Impacts

The primary goals of PPClin include increasing the number of clinical trials conducted in Brazil, improving access to innovative therapies for SUS patients, and boosting the country's contribution to global clinical research. Projections suggest clinical trials could generate up to R$63 billion annually, highlighting the economic potential.

By integrating research more closely with SUS, the program aims to ensure that findings directly benefit the Brazilian population while attracting foreign investment. Stakeholder perspectives emphasize the need for transparent governance and sustained funding to realize these benefits fully.

Photo by KOBU Agency on Unsplash

Challenges and Strategic Solutions

Despite the progress, challenges remain, including workforce constraints, logistical bottlenecks, and building public trust. The program incorporates strategies such as digital transformation, workforce professionalization, and differentiated approaches for rare diseases and priority populations.

Multistakeholder deliberations from the First Annual Clinical Research Meeting in May 2025 informed these directions, stressing coordinated policy action and patient-centered trial designs.

Stakeholder Perspectives and Future Outlook

Industry leaders, researchers, and patient advocates view the initiative positively, noting its potential to enhance Brazil's competitiveness. With regulatory predictability improving, experts anticipate a surge in trials, particularly in oncology and infectious diseases where Brazil's diverse population offers unique advantages.

Looking ahead, the program is expected to drive innovation, support technology transfer, and contribute to health system resilience. Continued investment and effective implementation will be crucial for long-term success.